New-Onset A-Fib Profiled in Patients Hospitalized With COVID-19
New-onset atrial fibrillation identified in about 1 in 20 patients hospitalized with COVID-19
Atrial Fibrillation
Early Rhythm Control May Benefit Low-Risk A-Fib Patients
Early rhythm control linked to reduced risk for cardiovascular complications for those meeting, not meeting eligibility for EAST-AFNET 4 trial
NDA Submitted for Landiolol, a Highly Cardioselective Beta Blocker
Landiolol is an ultra-short acting, cardioselective, beta-1 adrenoceptor blocker designed to reduce heart rate with a minimal effect over cardiac contractility.
NOACs May Be Better Choice for Patients With A-Fib and DM
Risks for diabetes complications, mortality lower with non-vitamin K antagonist oral anticoagulants versus warfarin
USPSTF: Evidence Still Lacking for Atrial Fibrillation Screening
Evidence currently inadequate for assessing the balance of benefits and harms of screening for atrial fibrillation in asymptomatic adults
Marine Omega-3 Supplements Tied to Higher Atrial Fibrillation Risk
Risk appeared to be greater in trials testing >1 g/day dosing
FDA: Risk of LAAO Implant-Related Adverse Events May Be Higher for Women
The analysis included 49,357 patients undergoing LAAO procedures with the Watchman Left Atrial Appendage Closure device.
Noncompliance to Apixaban for A-Fib Due to Many Factors
Improved communication with patients about cost, bleeding, and monitoring may increase compliance
Individual A-Fib Episodes Tied to Recent Alcohol Intake
AF episodes also linked to higher odds of peak blood alcohol concentration, total area under curve of alcohol exposure
Non-Vitamin K Antagonist Oral Anticoagulants vs Warfarin in NVAF Patients
Findings may help with decision-making in this high-risk patient population.
